Myriad, BioMarin enter into mutation testing agreement
SALT LAKE CITY—Myriad Genetics Inc. and biopharmaceutical company BioMarin Pharmaceutical Inc. have entered into an agreement to perform BRCA1 and BRCA2 mutation testing on patients that will be enrolled in BioMarin's Phase I/II clinical study of BMN, a novel PARP-inhibitor drug candidate for patients with advanced or recurring tumors. Per the agreement, Myriad will use its Comprehensive BRACAnalysis technology with large rearrangement testing in order to identify the presence of germline mutations in patients prior to study enrollment and will provide test reports to clinicians. Myriad's BRACAnalysis assesses a woman's risk for hereditary breast and ovarian cancer by analyzing the BRCA1 and BRCA2 genes. Myriad President and CEO Peter Meldrum says his company is "extremely pleased to be working with BioMarin on their exciting new clinical study focused on finding a more effective treatment for genetically-defined cancers."